Search Results
Your search for early matches 10332 pages
Showing 3301 - 3350Chronic Graft-vs-Host Disease: Future Directions in Treatment
Hematopoietic stem cell transplantation (HSCT) has improved survival rates for several hematologic malignancies, but as the number of transplants continues to rise, community oncologists are evaluating more posttransplant complications in the clinics. The ASCO Post spoke with two of the principals...
ASCO Statement on ‘Cancer Statistics, 2021’
ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, issued the following statement on “Cancer Statistics, 2021,” a report published annually by the American Cancer Society. “Fifty years after President Nixon signed the National Cancer Act to make...
Allogeneic Hematopoietic Cell Transplantation in Acute Leukemias and Myelodysplastic Syndromes
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the use of allogeneic hematopoietic cell transplantation (allo-HCT) in the...
Tenna V. Henriksen, PhD Candidate, on Colorectal Cancer: Circulating Tumor DNA Analysis to Improve Treatment
Tenna V. Henriksen, PhD Candidate, of Aarhus University, discusses her findings on how circulating tumor DNA may help assess recurrence risk and the benefit of adjuvant therapy, and more quickly detect early relapse after treatment in patients with colorectal cancer (Abstract 11).
Are Some Oral Pathogens More Common in Patients With Esophageal Cancer?
In a new study published by Kawasaki et al in the journal Cancer, researchers reported that certain oral pathogens are more prevalent in patients with esophageal cancer, and pointed out this information may be used as a novel diagnostic tool. The oral cavity is a rich source of microbial diversity, ...
Novel Risk Tool for Predicting Severe Toxicity in Older Patients Receiving Chemotherapy for Early-Stage Breast Cancer
As reported in the Journal of Clinical Oncology, Allison Magnuson, DO, and colleagues have developed a risk tool for predicting severe toxicity in patients aged 65 and older receiving chemotherapy for early-stage breast cancer. Study Details The prospective cohort study included 473 patients...
Empowering the FDA to Require Dose Optimization of All New Oncology Drugs
The vast majority of drugs used outside of oncology are evaluated in randomized dose-ranging trials to optimize the therapeutic index prior to the pivotal phase III trial. No one would think of dosing a statin or an antibiotic at the highest dose patients could tolerate, especially if that dose...
Single-Institution Study Finds Decrease in Cancer Screenings, Diagnoses During the First Wave of the COVID-19 Pandemic
Researchers have documented a substantial decline in cancer and precancer diagnoses at the Northeast's largest health-care system (Massachusetts General Brigham) during the first peak of the COVID-19 pandemic due to a drop in the number of cancer screening tests performed. These findings were...
Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex
In a study reported in a letter to the editor in The New England Journal of Medicine, Nassar et al identified the prevalence of the formerly “undruggable” KRAS G12C mutation across tumor types, race, and sex. As stated by the investigators, a recently reported early-phase clinical trial has shown...
Electronic Patient Self-Reporting of Adverse Events During Cancer Chemotherapy: eRAPID System
In a single-institution phase III trial reported in the Journal of Clinical Oncology, Absolom et al found that use of the electronic patient self-reporting of adverse events: patient information and advice (eRAPID) system was associated with improvements in patient-reported outcomes vs usual care...
Postsurgical Disease Recurrence in Stage I to III Colorectal Cancer May Be Predicted by ctDNA
Patients with stage I to III colorectal cancer and a high risk for disease recurrence may be identified by serial testing of circulating tumor DNA (ctDNA) after resection, according to a study in which ctDNA was more reliable than carcinoembryonic antigen (CEA) surveillance or standard radiologic...
Study Finds Artificial Intelligence May Help to Identify New Risk Factors for Early-Onset Colorectal Cancer
Electronic health record–based artificial intelligence may help uncover new risk factors in the development of early-onset colorectal cancer, according to study findings presented by Parker et al at the AACR Virtual Special Conference: Artificial Intelligence, Diagnosis, and Imaging (Abstract...
Expert Point of View: Ajay K. Nooka, MD, MPH
Ajay K. Nooka, MD, MPH, Associate Professor of Hematology and Medical Oncology at Emory University and Medical Director, Winship Research Informatics Shared Resource at Winship Cancer Institute, Atlanta, considered the presentations on bispecific T-cell–engaging antibodies in myeloma to be among...
New Targets Explored for Bispecific T-Cell–Engaging Antibodies in Myeloma
B-cell maturation antigen (BCMA) is the most frequent target of immunotherapies in relapsed or refractory multiple myeloma, but bispecific T-cell–engaging (BiTE) antibodies with novel targets are also achieving promising results. Studies presented at the 2020 American Society of Hematology (ASH)...
Expert Point of View: Alphonse G. Taghian, MD
Alphonse G. Taghian, MD, Professor at Harvard Medical School and Co-Director of Breast Cancer Research Program at Massachusetts General Hospital, Boston, said that these results from the PRIME II trial are quite similar to those of the older CALGB study first initiated in 1994.1 Both studies had a ...
Can Postoperative Whole-Breast Irradiation Be Safely Omitted in Older Women With Low-Risk Breast Cancer?
Omitting postoperative radiotherapy with whole-breast irradiation may not compromise 10-year overall survival or increase the risk of developing metastasis in most women 65 years and older with low-risk breast cancer, according to results of the large randomized PRIME II trial reported at the 2020...
Record Drop in Cancer Mortality for Second Straight Year Due to Improved Lung Cancer Treatment Reported in ‘Cancer Statistics, 2021’
Overall cancer death rates in the United States dropped continuously from 1991 through 2018, for a total decrease of 31%, including a 2.4% decline from 2017 to 2018. These findings were reported in the American Cancer Society’s “Cancer Statistics, 2021” article, published by Rebecca L. Siegel, MPH, ...
FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health-Care Providers and Clinical Laboratory Staff
The U.S. Food and Drug Administration (FDA) is alerting clinical laboratory staff and health-care providers that it is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests....
Does Following a Mediterranean Diet Reduce the Risk of Disease Progression in Men on Active Surveillance for Prostate Cancer?
In a study examining the effect of a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style...
Subcutaneous Fixed-Dose vs Intravenous Pertuzumab/Trastuzumab for HER2-Positive Early Breast Cancer
As reported in The Lancet Oncology by Tan et al, the phase III FeDeriCa trial showed comparable pharmacokinetics and pathologic complete response rates with a subcutaneous (SC) fixed-dose combination of pertuzumab and trastuzumab vs the same combination administered intravenously (IV)—both given...
New Study Explores the Use of Focused Ultradeep DNA Sequencing to Quantify Skin Cancer Risk
Recent research has shed new light on the carcinogenic effect of exposure to ultraviolet (UV) radiation, laying the groundwork for improvements in skin cancer risk stratification and prevention. A study published by Lei Wei, PhD, and colleagues in Science Advances detailed a method to measure the...
Adjuvant Gefitinib vs Vinorelbine/Cisplatin in Stage II–IIIA EGFR-Mutant NSCLC: Final Overall Survival Analysis
As reported in the Journal of Clinical Oncology by Zhong et al, the final overall survival results of the phase III CTONG1104 trial indicated no significant advantage of adjuvant gefitinib vs vinorelbine/cisplatin in patients with EGFR-mutant stage II–IIIA (N1–2) non–small cell lung cancer ...
Multiancestry Meta-analysis of Prostate Cancer Genetics
A research team has published findings from a study that brought together data from genomic prostate cancer studies. Including more than 200,000 men of European, African, Asian, and Hispanic ancestry from around the world, the study is reportedly the largest, most diverse genetic analysis ever...
Use of a Novel CAR T-Cell Therapy in Pediatric and Adult Patients With Advanced B-Cell ALL
Pooled results of two phase I studies, reported in The Lancet by Benjamin et al, indicate that the genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell product UCART19 is active and has a manageable toxicity profile in pediatric and adult patients with relapsed...
Global Burden of Cervical Cancer and Association With HIV
A research team has quantified the effects of infection with the human immunodeficiency virus (HIV) on the development of cervical cancer. Their results show that the risk of developing cervical cancer is six times higher in women who are infected with HIV, and that women who live in Southern and...
Neoadjuvant Chemotherapy and Overall Survival in Metastatic Endometrial Cancer
In a National Cancer Database analysis reported in JAMA Network Open, Tobias et al found that receipt of neoadjuvant chemotherapy was associated with improved short-term but not long-term survival vs primary debulking surgery in patients with metastatic endometrial cancer. As stated by the...
GLOBOCAN 2020 Database Provides Latest Global Data on Cancer Burden, Cancer Deaths
On December 15, the International Agency for Research on Cancer (IARC) released the latest estimates on the global burden of cancer. The GLOBOCAN 2020 database, accessible online as part of the IARC Global Cancer Observatory, provides estimates of incidence and mortality in 185 countries for 36...
American Cancer Society Report Identifies Critical Gaps and Research Opportunities for Improved Cancer Care
A new report found that despite progress in the decline of cancer mortality, there are still critical gaps, including the need to develop better tools and explore research opportunities that would lead to limiting cancer as a major health concern. This blueprint article completes an eight-part...
NIH RADx-rad Grants Support Investigation of Novel COVID-19 Testing and Surveillance Approaches
The National Institutes of Health (NIH) has awarded over $107 million to support new, nontraditional approaches and reimagined uses of existing tools to address gaps in COVID-19 testing and surveillance. The program will also develop platforms that can be deployed in future outbreaks of COVID-19...
New Recommendations for Advancing the Scholarly Discipline of Global Oncology
New recommendations aimed at advancing the status of global oncology as an academic discipline were published in November as a special article in JCO Global Oncology.1 The field of global oncology is important. According to the World Health Organization,2 cancer is the second-leading cause of death ...
The Heart of Catherine Handy Marshall, MD, MPH’s Work
In 2017, Women Who Conquer Cancer (WWCC) awarded Catherine Handy Marshall, MD, MPH, a Conquer Cancer Young Investigator Award (YIA) grant to explore the impact of cardiovascular disease risk factors on cancer outcomes. Three years after receiving the WWCC YIA, Dr. Handy Marshall is pursuing...
Pembrolizumab Plus Chemotherapy for Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer
On November 13, 2020, pembrolizumab (Keytruda) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for use in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer with tumors expressing PD-L1 (Combined ...
Roswell Park Experts Named to Highly Cited Researchers List
Roswell Park Comprehensive Cancer Center’s Igor Puzanov, MD, MSCI, FACP, Andrew Hyland, PhD, and Maciej Goniewicz, PhD, PharmD, have all recently been recognized as global scientific pioneers on Clarivate Plc’s Highly Cited Researchers list for 2020. The list recognizes researchers who have...
Anthony Fauci, MD, Encourages Patients With Cancer to Receive COVID-19 Vaccine
The American Society of Hematology (ASH) President Stephanie Lee, MD, MPH, sat down with Anthony Fauci, MD, Director of the National Institutes of Allergy and Infectious Diseases (NIAID) and medical advisor to President-Elect Joseph Biden, for a virtual fireside chat about COVID-19 and cancer at...
Expert Point of View: Cathy Eng, MD
Cathy Eng, MD, the David H. Johnson Chair in Surgical and Medical Oncology, Co-Leader of the Gastrointestinal (GI) Cancer Research Program, and Co-Director of GI Oncology at Vanderbilt-Ingram Cancer Center in Nashville, as well as Vice Chair of the SWOG GI Committee, said she found the study’s...
Study Reports Highly Skilled Surgeons Significantly Reduce Death From Colon Cancer
To improve long-term survival odds, individuals with early-stage colon cancer should have their surgery performed by highly skilled surgeons. In a study that used video assessment, surgeons with highly ranked skills gave their patients a 69% lower risk of dying at 5 years as compared with their...
FDA Approves Adjuvant Osimertinib for EGFR-Mutated NSCLC
On December 18, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) for adjuvant therapy after tumor resection in patients with non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as...
Sue S. Yom, MD, PhD, FASTRO, Named Editor-in-Chief of ASTRO’s Red Journal
The American Society for Radiation Oncology (ASTRO) announced the appointment of Sue S. Yom, MD, PhD, FASTRO, as Editor-in-Chief of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), ASTRO’s flagship scientific journal. Dr. Yom, who is Vice Chair and Distinguished...
Panel on Global Cancer Control Looks for Ways Forward in a War That’s Proving Hard to Win
Are we winning the war on cancer? It’s not so clear, especially with COVID-19 poised to erase recent gains, panelists said at a session on global cancer control at the 2020 European Cancer Summit, which was sponsored by the European Cancer Organisation. “We know what we have to do. My question is...
Addressing Inequality in Cancer Care on a Global Scale
It has become a familiar theme of late: Inequities exist in all aspects of cancer care. Although study after study documents problems with access to care and poorer cancer outcomes among underrepresented groups, less is heard about organized efforts to address these issues. This critical topic was...
Expert Point of View: Omid Hamid, MD
Omid Hamid, MD, Chief of Research/Immuno-Oncology at The Angeles Clinic & Research Institute and Co-Director of the Cutaneous Malignancy Program at Cedars-Sinai Cancer Center, Los Angeles, commented on the investigational use of bempegaldesleukin in melanoma. “The role of interleukin-2 [Il-2]...
Novel Combination Under Study in First-Line Treatment of Metastatic Melanoma
A first-line regimen combining the novel interleukin-2 (Il-2) agonist bempegaldesleukin (NKTR-214) with nivolumab showed encouraging clinical activity in patients with metastatic melanoma in the phase I/II PIVOT-02 trial, according to a presentation during the 2020 Annual Meeting of the Society for ...
Expert Point of View: Laura Dawson, MD
Laura Dawson, MD, Professor of Radiation Oncology at the University of Toronto and Princess Margaret Cancer Centre, viewed these initial study results as “a strong signal with high promise.” “Radiation therapy improves local control and delays local disease progression in patients with pancreatic...
Novel Radiomodulation Approach With Dismutase Mimetic Plus SBRT in Resectable Pancreatic Cancer
Pancreatic cancer is one of the most aggressive, lethal malignancies, and life-extending treatments represent a critical unmet need. A pilot study suggests a potential way forward for patients with nonmetastatic unresectable or borderline resectable pancreatic cancer may be a combination of...
CTC Enumeration Predicts Survival Early in Treatment of Metastatic Breast Cancer
The number of circulating tumor cells (CTCs) assessed at baseline and at about 1 month after cancer-directed treatment was strongly associated with overall survival in patients with metastatic breast cancer, according to a large retrospective pooled analysis reported at the 2020 San Antonio Breast...
ASH Announces Donation of Next-Generation Sequencing Equipment to Countries in the International Consortium
The American Society of Hematology (ASH) recently announced the donation of next-generation sequencing equipment to six reference laboratories in five countries in Latin America. These countries constitute the International Consortium on Acute Leukemia (ICAL), a clinical network supported by the...
Expert Point of View: Robert A. Brodsky, MD
Robert A. Brodsky, MD, Professor of Medicine and Oncology and Director of the Division of Hematology, Johns Hopkins School of Medicine, Baltimore, included this late-breaking abstract among his picks of noteworthy abstracts at the meeting, in a press briefing with journalists. “The researchers...
First Sign of Myeloproliferative Neoplasms May Be in Utero
Genetic mutations linked to myeloproliferative neoplasms emerge in childhood or even in utero, decades before they cause cancer, according to a late-breaking abstract presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 “Our preliminary findings show these...
My Life of Service to Other Cancer Survivors
Six months before my diagnosis of metastatic colorectal cancer, in 2016, at age 38, I told my mom, “I feel like I’m dying.” Even though more than 10 specialists I had seen over the previous 8 years for unexplained bouts of abdominal pain and bloating, fatigue, and constipation kept assuring me that ...
Fan Therapy May Relieve Breathlessness Associated With Advanced Cancers
Blowing air from a fan into the face of patients with advanced cancer experiencing breathlessness—and other nonpharmacologic interventions—may offer symptomatic relief, according to new research directed by Johns Hopkins Kimmel Cancer Center investigators and published in JAMA Oncology.1 In...
